Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 1;31(4):811-820.
doi: 10.1158/1055-9965.EPI-21-0869.

A Predictive Model of Noncardia Gastric Adenocarcinoma Risk Using Antibody Response to Helicobacter pylori Proteins and Pepsinogen

John D Murphy  1 , Andrew F Olshan  1 , Feng-Chang Lin  2 , Melissa A Troester  1 , Hazel B Nichols  1 , Julia Butt  3 , You-Lin Qiao  4 , Christian C Abnet  5 , Manami Inoue  6 , Shoichiro Tsugane  6 , Meira Epplein  7
Affiliations

A Predictive Model of Noncardia Gastric Adenocarcinoma Risk Using Antibody Response to Helicobacter pylori Proteins and Pepsinogen

John D Murphy et al. Cancer Epidemiol Biomarkers Prev. .

Abstract

Background: Blood-based biomarkers for gastric cancer risk stratification could facilitate targeting screening to people who will benefit from it most. The ABC Method, which stratifies individuals by their Helicobacter pylori infection and serum-diagnosed chronic atrophic gastritis status, is currently used in Japan for this purpose. Most gastric cancers are caused by chronic H. pylori infection, but few studies have explored the capability of antibody response to H. pylori proteins to predict gastric cancer risk in addition to established predictors.

Methods: We used the least absolute shrinkage and selection operator (Lasso) to build a predictive model of noncardia gastric adenocarcinoma risk from serum data on pepsinogen and antibody response to 13 H. pylori antigens as well as demographic and lifestyle factors from a large international study in East Asia.

Results: Our best model had a significantly (P < 0.001) higher AUC of 73.79% [95% confidence interval (CI), 70.86%-76.73%] than the ABC Method (68.75%; 95% CI, 65.91%-71.58%). At 75% specificity, the new model had greater sensitivity than the ABC Method (58.67% vs. 52.68%) as well as NPV (68.24% vs. 66.29%).

Conclusions: Along with serologically defined chronic atrophic gastritis, antibody response to the H. pylori proteins HP 0305, HP 1564, and UreA can improve the prediction of gastric cancer risk.

Impact: The new risk stratification model could help target more invasive gastric screening resources to individuals at high risk.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The authors declare no conflicts of interest for this research project.

Figures

Figure 1:
Figure 1:
Receiver-operating characteristic curve for classification of gastric cancer in a subset of the Helicobacter pylori Biomarker Cohort Consortium (n=1422). This figure compares the gastric cancer discrimination performance of the Lasso model (solid) to that of the ABC Method (dashed) within the training data set. Dots represent the threshold of gastric cancer risk score > 1 at which sensitivity and specificity were calculated for both models.
Figure 2:
Figure 2:
Sensitivity analysis. Receiver-operating characteristic curve for classification of gastric cancer in a subset of the Helicobacter pylori Biomarker Cohort Consortium (n=1422). This figure compares the gastric cancer discrimination performance of the Lasso model including pepsinogen I (solid) to that of the ABC Method (dashed) and the Lasso model without pepsinogen I (dot-dashed) within the training data set. Points represent the threshold of gastric cancer risk score > 1 at which sensitivity and specificity were calculated for both models
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi: 10.1002/ijc.29210 - DOI - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492 - DOI - PubMed
    1. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System. Lyon, France: IARC; 2010. World Heal Organ Classif Tumours. 3.
    1. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet (London, England). 2015;385(9972):977–1010. doi: 10.1016/S0140-6736(14)62038-9 - DOI - PMC - PubMed
    1. Colquhoun A, Arnold M, Ferlay J, Goodman KJ, Forman D, Soerjomataram I. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut. 2015;64(12):1881–1888. doi: 10.1136/gutjnl-2014-308915 - DOI - PubMed

Publication types